Details of the Drug

General Information of Drug (ID: DM4UVTO)

Drug Name
SYN125
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Uterine serous carcinoma 2C72.1 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DG4YF6
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04363242) A Study to Find the Maximum Tolerated Dose (MTD) of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People With Cancer of the Internal or External Lining of the Body.. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Symphogen.